• Our Professionals
  • Our Work
  • Our Insights
  • Firm
  • Careers
  • Tools
Finnegan
    • AIA Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • IP FDA Blog
    • Prosecution First Blog
  • Articles
  • IP Updates
  • Podcasts
  • Events
  • Webinars
  • Books

Article

Licensing Patents to Competitors Could Weigh Against Granting an Injunction

May 23, 2017

LES Insights

By John C. Paul; D. Brian Kacedon; Lauren J. Dowty

Authored by Lauren J. Dowty, D. Brian Kacedon, and John C. Paul

Abstract

After finding an LED manufacturer’s patents were infringed, one district court refused to grant a permanent injunction to prevent the infringing party from selling its LEDs. The Federal Circuit affirmed the district court’s denial of the injunction, reasoning that the injunction was not necessary to protect the patent holder from irreparable harm, in part because the LED manufacturer had previously licensed several of its competitors.


After succeeding on an infringement claim, a patent owner may seek a permanent injunction to prevent the infringer from marketing or selling infringing products in the future. Injunctions, however, are not granted as a matter of course. Rather, a patent holder must prove that it would suffer irreparable harm without the injunction. Recently, in Nichia Corp. v. Everlight Americas, Inc., the U.S. Court of Appeals for the Federal Circuit found that prior licenses granted by the patentee to some of its competitors could be considered in determining whether the patentee would be irreparably harmed without an injunction. Relying in part on these prior licenses, the court affirmed the district court’s denial of Nichia’s request for an injunction.

Background

Nichia sued Everlight for infringing its patents covering LED manufacturing methods and package designs. Following a trial, the court issued a ruling that Everlight infringed the patents and Nichia asked the court to issue a permanent injunction preventing Everlight from marketing or selling its infringing products. The district court denied Nichia’s request, finding that Nichia failed to prove that it would be irreparably harmed without an injunction. To be entitled to a permanent injunction, a patentee must prove: (1) that it has suffered an irreparable injury; (2) that remedies available at law, like monetary damages, are inadequate to compensate for that irreparable injury; (3) that, considering the balance of hardships between the plaintiff and defendant, a remedy in equity is warranted; and (4) that the public interest would not be disserved by a permanent injunction. Nichia provided evidence of only one lost sale to support its claim of irreparable harm. The district court concluded, however, that Nichia’s evidence did not even prove a single lost sale because there were several other lower-priced and licensed competitors that had the same sales opportunity. And because several of Nichia’s licensees sold competing products at lower prices, the district court found that Nichia did not prove that Everlight’s infringement caused any price erosion that damaged Nichia. The district court found, instead, that Nichia’s licensing activities and the resulting sales of competing products changed the market by making multiple low-priced alternatives available. Nichia appealed, arguing in part, that the district court improperly considered Nichia’s licensing activities in determining whether Nichia would be irreparably harmed absent a permanent injunction.

The Federal Circuit Decision

The Federal Circuit explained that although patent ownership grants a patentee the right to exclude others from practicing a patented invention, an injunction in patent law requires proof, under the four-factor test, that the patent holder would be irreparably harmed without one. The Federal Circuit rejected Nichia’s argument that courts cannot consider patent licenses in determining irreparable harm under the four-factor test, finding instead that the patentee’s licenses could weigh against a finding of irreparable harm. The court explained that Nichia’s granting of licenses, the identity of licensees, the experience in the market since granting the licenses, and the identity of the accused infringers could all affect the court’s analysis of whether irreparable harm. The Federal Circuit stated that regardless of the district court’s licensing analysis, it properly treated the licenses as an independent ground for denying Nichia’s request for an injunction. More particularly, rather than relying on its licensing analysis alone, the district court found the licenses bolstered its separate finding that Nichia failed to establish market competition, lost sales, and price erosion. The Federal Circuit agreed with these findings—all of which weighed against concluding that Nichia would suffer irreparable harm absent an injunction.

Strategy and Conclusion

Granting patent licenses to competitors may make it difficult to get injunctions against other competitors, allowing them to stay on the market with an ongoing royalty despite infringement.

Further Information

The Nichia opinion can be found here.

Tags

United States Court of Appeals for the Federal Circuit (CAFC)

Related Practices

Patent Litigation

Appeals

Related Industries

Chemical, Industrial, and Materials

Manufacturing

Related Professionals

 John_Paul
John C. Paul
Partner
Washington, D.C.
+1 202 408 4109
Email
D_Brian_Kacedon
D. Brian Kacedon
Partner
Washington, D.C.
+1 202 408 4301
Email
Lauren_Dowty
Lauren J. Dowty
Associate
Washington, D.C.
+1 202 408 4426
Email

Copyright © Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.

Related Insights

Conference

Best Practices in Intellectual Property 2021

June 14-15, 2021

Tel Aviv

Webinar

Patent Law Institute 2021: Critical Issues & Best Practices

April 29-30, 2021

Webinar

Webinar

Patent Law Institute 2021: Critical Issues & Best Practices

April 1-2, 2021

Webinar

Seminar

FORUM!Live: Patent Claim Construction

March 24-25, 2021

Virtual

Webinar

Litigation Holds: Creating Effective Notices, Implementing Efficient Collection Processes, Protecting Privilege

March 17, 2021

Webinar

Webinar

Patent Claim and Specification Drafting and Prosecution

March 11, 2021

Webinar

Webinar

Patent Year in Review: Key Decisions, Trends, and Strategies

February 25, 2021

Webinar

Conference

Pharma & Biotech Patent Litigation in Europe

February 23-25, 2021

Virtual

Webinar

Patenting Pharmaceutical Drug Formulations: Withstanding Litigation and PTAB Challenges

February 16, 2021

Webinar

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

  • Privacy
  • Disclaimer
  • EEO Statement

© 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP